Bertek apomorphine clears FDA
Executive Summary
Mylan subsidiary Bertek will launch Apokyn (apomorphine) as the first therapy approved to treat "off" episodes of Parkinson's disease by July after receiving FDA approval of the orphan drug product April 20...
You may also be interested in...
Bertek Apokyn To Launch By July; Combo Antiemetic Use Study Planned
Bertek's postmarketing commitments for Apokyn (apomorphine) include a study of concomitant use with the antiemetic trimethobenzamide
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.